# LIBERTAS: HCP commentary report

> 813 verified statements (423 from clinicians verified by NPI or staff page) from 56 commentary sources · 12 findings · updated Nov 3, 2026

## Report

- Trial: A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- NCT ID: NCT05884398
- Registry: https://clinicaltrials.gov/study/NCT05884398
- Sponsor: Janssen Research & Development, LLC
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs tested: apalutamide
- Indication: metastatic castration-sensitive prostate cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-03 UTC
- Last checked: 2026-11-03 UTC
- Updated: 2026-11-03 UTC
- Release hash: dce4f2d465ab2039a0d01eb7424ec7e05cc4963a48e4487cb5bff3a183eba639

## Counts

- Commentary sources screened: 92
- Sources cited by verified statements: 57
- Verified statements: 813
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 423
- Findings: 12
- Named people in screened sources (unnamed speakers and accounts not counted): 50
- Voices cited: 50
- Cited voices with a verified identity: 43
- Cited clinicians, voices with a confirmed clinical role (the abstract's clinicians): 39
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 38
- By role and specialty (the abstract's specialty counts):
  - 18 physician
  - 12 physician, Medical oncology
  - 4 physician, Urology
  - 3 physician, Radiation oncology
  - 1 physician assistant
  - 1 physician, Surgical oncology
- Organisational or shared accounts (not counted as people): 4

A verified identity says who a voice is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified voices without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

LIBERTAS tests intermittent versus continued androgen-deprivation therapy (ADT) with apalutamide after PSA response in metastatic castration-sensitive prostate cancer; selective breaks before prospective stopping evidence remain contested. The report cites 38 physicians, including 12 medical oncologists, and one physician assistant; a medical oncologist reports co-chairing LIBERTAS. Whether PSA alone can guide stopping remains open, alongside questions about treatment burden and testosterone recovery. Which patients, stopping plans, monitoring requirements and uncertainties should an ADT-sparing discussion make explicit?

## Open Medical Affairs question

Which patients, stopping strategy, monitoring requirements and uncertainties should an ADT-sparing discussion make explicit?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Whether selective treatment breaks are acceptable before prospective stopping evidence
- F2. Clinicians emphasize deep PSA response; whether PSA alone can guide stopping remains open
- F3. Whether ADT withdrawal alone meets patients' goals—and how it differs from stopping both drugs
- F4. Clinicians favor selective stopping discussions in lower-burden disease, with high-risk and competing-risk qualifications
- F5. Speakers find interruption precedents informative but qualify extrapolation across studies
- F6. Speakers see an ADT-sparing role for local treatment but question repeated lesion-only management
- F7. Clinicians favor an ARPI doublet over routine ADT alone, while preserving selective non-intensification and observation
- F8. Whether and when docetaxel adds benefit beyond ADT–ARPI in response-adapted mHSPC care
- F9. Clinicians seek molecular and imaging work-up to refine treatment intensity beyond PSA or lesion counts
- F10. Clinicians weigh treatment burden, testosterone recovery and symptom attribution—not simply time off medication
- F11. Speakers make access, specialist competence and patient support practical conditions for treatment plans
- F12. Contributors welcome LIBERTAS research and inclusion; one clinician defends its industry sponsorship

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 64 | 59 | 16 | 13 | recorded | 2 |
| F2 | 48 | 38 | 18 | 19 | recorded | 2 |
| F3 | 64 | 53 | 21 | 26 | recorded | 2 |
| F4 | 53 | 37 | 15 | 16 | recorded | 2 |
| F5 | 74 | 70 | 13 | 12 | recorded | 2 |
| F6 | 117 | 124 | 9 | 14 | recorded | 4 |
| F7 | 89 | 95 | 12 | 14 | recorded | 4 |
| F8 | 90 | 86 | 15 | 14 | recorded | 4 |
| F9 | 61 | 45 | 8 | 9 | recorded | 2 |
| F10 | 90 | 83 | 17 | 23 | recorded | 3 |
| F11 | 43 | 53 | 7 | 9 | recorded | 1 |
| F12 | 18 | 18 | 14 | 7 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 34 | 12 | 12 | 0 | 6 | 81 | 12 | 5 posts and articles, 11 podcasts and video | yes |
| F2 | 37 | 4 | 0 | 1 | 6 | 51 | 4 | 6 posts and articles, 12 podcasts and video | yes |
| F3 | 21 | 12 | 7 | 4 | 20 | 68 | 3 | 7 posts and articles, 14 podcasts and video | yes |
| F4 | 30 | 7 | 3 | 4 | 9 | 59 | 11 | 4 posts and articles, 11 podcasts and video | yes |
| F5 | 37 | 6 | 3 | 7 | 21 | 98 | 13 | 4 posts and articles, 9 podcasts and video | yes |
| F6 | 63 | 18 | 10 | 4 | 22 | 160 | 37 | 2 posts and articles, 7 podcasts and video | yes |
| F7 | 57 | 3 | 4 | 10 | 15 | 123 | 13 | 12 podcasts and video | yes |
| F8 | 57 | 10 | 9 | 8 | 6 | 115 | 10 | 2 posts and articles, 13 podcasts and video | yes |
| F9 | 43 | 5 | 5 | 2 | 6 | 69 | 5 | 8 podcasts and video | yes |
| F10 | 39 | 14 | 17 | 1 | 19 | 106 | 15 | 4 posts and articles, 13 podcasts and video | yes |
| F11 | 25 | 7 | 4 | 0 | 7 | 56 | 6 | 7 podcasts and video | yes |
| F12 | 17 | 0 | 0 | 0 | 1 | 18 | 0 | 14 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Percentage of Participants With 18-Months Radiographic Progression-free Survival (rPFS): no finding draws on it directly
- Primary endpoint: Percent Change From Randomization in Severity of Adjusted Hot Flash Score at 18 Months: F3 (3 shared claims), F10 (3 shared claims)
- Secondary endpoints: F2 (16 shared claims), F3 (2 shared claims), F10 (6 shared claims)
- Population and setting: F4 (18 shared claims), F6 (1 shared claims), F8 (1 shared claims)
- The comparison: F3 (23 shared claims), F5 (1 shared claims), F6 (2 shared claims)
- Safety and tolerability: F1 (1 shared claims), F7 (2 shared claims), F8 (2 shared claims), F10 (35 shared claims)
- Design and conduct: F1 (1 shared claims), F2 (2 shared claims), F3 (9 shared claims), F5 (2 shared claims)

## Abbreviations

- ADT: androgen deprivation therapy
- ARPI: androgen receptor pathway inhibitor
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- PSA: prostate-specific antigen

## Sample findings

Paraphrased; the full report links each statement to its source.

### F2. Clinicians emphasize deep PSA response; whether PSA alone can guide stopping remains open

A radiation oncologist on X asked how treatment-reduction trials using PSA thresholds, including LIBERTAS and EORTC De-escalate, should be designed.

Source: X thread, 2024-03-13.

### F3. Whether ADT withdrawal alone meets patients' goals—and how it differs from stopping both drugs

A contributor on X asked whether LIBERTAS had considered broader quality-of-life measurement among its endpoints.

The contributor's clinical role is not stated in the sources reviewed for this edition.

Source: X thread.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 12 | Titles free |
| Detailed analysis | 21 sections | Paid |
| Verified statements with short source quotes and links | 813 | Paid |
| Who said each statement, with each cited voice's role and what confirmed it (NPI registry or staff page) | 50 | Every edition |
| Trial aspects mapped | 16 | Free |
| Sources with links | 57 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
| Verified speaker IDs as data (NPI, social and scholarly IDs) | 43 | 12-month plan add-on |

Every edition, the free report included, names who said each statement, as the source shows them. Each named voice's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 39 of the 50 cited voices have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key. The verified speaker identities add-on, sold with 12-month plans, adds each verified person's IDs as data (the NPI number, X, Bluesky and LinkedIn accounts, ORCID and institutional pages), so your team can check each attribution itself. It is for checking attribution inside your organization, never for outreach or targeting, and it does not unlock who said what.

## Trial aspects

15 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Percentage of Participants With 18-Months Radiographic Progression-free Survival (rPFS) | no commentary found | 0 | 0 |
| Primary endpoint: Percent Change From Randomization in Severity of Adjusted Hot Flash Score at 18 Months | discussed | 6 | 4 |
| Secondary endpoints | discussed | 24 | 7 |
| Population and setting | discussed | 20 | 9 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 26 | 18 |
| Safety and tolerability | discussed | 40 | 10 |
| Design and conduct | discussed | 14 | 10 |
| Acting before prospective stopping evidence | discussed | 28 | 10 |
| Historical and adjacent interruption evidence | discussed | 43 | 7 |
| Response depth, discordant progression and restart decisions | discussed | 28 | 13 |
| Local treatment as an alternative or addition around systemic-treatment reduction | discussed | 50 | 6 |
| Initial doublet treatment, selective intensification, prognostic work-up and reasons to withhold treatment | discussed | 53 | 10 |
| Molecular and imaging work-up for individualized intensity | discussed | 44 | 8 |
| Patient willingness, reassurance and the experience of uncertainty | discussed | 27 | 7 |
| Affordability, coordinated care and patient support | discussed | 40 | 7 |
| Study reception, inclusive participation and sponsorship | discussed | 18 | 14 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 67 | 34 |
| Podcasts | 13 | 12 |
| YouTube | 9 | 9 |
| Bluesky threads | 3 | 1 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2023-06-15 to 2026-11-01
- Cited window: 2023-06-24 to 2026-11-01
- Retrieved: 2026-11-03

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- Registry: NCT05884398 (https://clinicaltrials.gov/study/NCT05884398)
- Study IDs: CR109327 · 56021927PCR3020 (Janssen Research & Development, LLC) · 2022-502686-24-00 (EUCT number)
- Sponsor: Janssen Research & Development, LLC
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 420 (actual)
- Start: 2023-08-31 (actual)
- Primary completion: 2026-10-12 (estimated)
- Primary endpoint: Percentage of Participants With 18-Months Radiographic Progression-free Survival (rPFS) (From randomization (Day 1 of Cycle 7) up to 18 months)
- Primary endpoint: Percent Change From Randomization in Severity of Adjusted Hot Flash Score at 18 Months (From randomization (Day 1 of Cycle 7) up to 18 months)
- Intervention: Apalutamide (drug)
- Intervention: Androgen-deprivation Therapy (ADT) (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.
- Not yet captured in this edition: a view on manufacturer-attributed guidance for managing apalutamide-associated rash with antihistamines and topical corticosteroids.
- Not yet captured in this edition: a view on genetic testing and treatment selection for aggressive management of high-volume metastatic castration-sensitive prostate cancer.
- Not yet captured in this edition: a view on counseling, assessment, dose reduction and discontinuation for apalutamide-associated rash.
- Not yet captured in this edition: a view on apalutamide rash management and treatment discontinuation in metastatic castration-sensitive prostate cancer.
- Not yet captured in this edition: a question about stopping ADT after response to apalutamide plus ADT while preserving disease control and reducing side effects.
- Not yet captured in this edition: a view on treatment de-escalation and quality of life in responding metastatic hormone-sensitive prostate cancer.
- Not yet captured in this edition: a view on genetic testing and initial treatment selection in synchronous high-volume metastatic castration-sensitive prostate cancer.
- Not yet captured in this edition: a view on rash counseling, treatment interruption, assessment, dose reduction, discontinuation and severity grading during apalutamide treatment.
- Not yet captured in this edition: a view on relapse timing as a guide to selecting patients for metastasis-directed therapy.
- Not yet captured in this edition: a view on grouping nearby metastatic nodes when selecting local treatment to enable time off ADT.
- Not yet captured in this edition: a view on manufacturer guidance for antihistamines and topical corticosteroids to manage apalutamide-associated rash.
- Not yet captured in this edition: a view on potentially short-lived treatment sensitivity when weighing treatment intensity in metastatic hormone-sensitive prostate cancer.
- Not yet captured in this edition: a view on androgen-receptor pathway intensification versus ADT monotherapy in metastatic castration-sensitive prostate cancer.
- 136 passages in 60 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 650 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; 37 sources about other trials or topics are not included.
- Repeated posts, reposts and copies of recordings do not establish additional independent endorsements. Where copies assign the same words to different people, the report keeps those words unnamed and does not count them as separate agreement.
- No full protocol or exact-trial results publication was available. Spoken descriptions of treatment allocation sometimes differ, and early PSA or symptom observations do not establish the randomized effects of intermittent versus continued ADT.
- Historical intermittent-ADT studies, EMBARK, ADREAM and other response-guided studies involve different settings, treatment components or stopping rules. Their findings remain attributed supporting arguments, not LIBERTAS results.
- Clinical anecdotes, reported conference votes and hypothetical patient examples do not establish comparative efficacy, safety or the frequency of a practice. Some testosterone-replacement anecdotes do not specify the patient's disease stage.
- Trial involvement and company relationships are described as the sources describe them. Those perspectives are not presented as independent validation, and research identity does not add evidentiary weight.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Reimbursement interpretations, affordability mechanisms and practice descriptions are local and time-specific. They are not confirmation of current coverage rules, and statements made at different times do not by themselves establish a change of mind.
- Parts of the funding discussion and some practical treatment questions were not fully assessed, so the range of arguments supporting or challenging those views may be understated.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-03 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes how the published edition states something, such as a count, a name or a sentence, without making a new edition, so the version stays the same. Every correction is listed here with its date. Last checked for new commentary 2026-11-03 UTC. No corrections.

## Offer

- Size: Deep (813 verified statements)
- Current edition: $1,950. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $3,400
- 6 months of weekly updates: $4,900
- 12 months of weekly updates: $6,800
- Optional verified speaker identities (12-month updates only, product updates-12-identities; speakers are named and described in every report): the NPI and other verified IDs, to check that each statement is attributed to the right person, never for outreach or targeting, at $15 per identity-verified person in the edition at purchase (43 now), at most $1,950; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/libertas-nct05884398
- Agents: POST https://www.erudio.com/api/orders with {"report": "libertas-nct05884398", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=libertas-05884398

## Cite

Erudio Health. LIBERTAS (NCT05884398): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 3, 2026. https://www.erudio.com/reports/libertas-nct05884398

## Machine access

- JSON: https://www.erudio.com/reports/libertas-nct05884398.json
- Markdown: https://www.erudio.com/reports/libertas-nct05884398.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "libertas-nct05884398"}`